Since atherosclerosis is regarded as a chronic low level inflammatory disease [15–18], we hypothesized that targeting PTP1B activity using a PTP1B-specific inhibitor trodusquemine [19], could prove effective in prevention and possibly reversal of atherosclerotic plaque formation. This evidence concerns the gene PTPN1 and atherosclerosis.